PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.04
Negative P/E while Healthcare median is -2.72. Seth Klarman would scrutinize path to profitability versus peers.
5628.35
P/S exceeding 1.5x Healthcare median of 11.96. Jim Chanos would check for potential multiple compression risks.
1.76
P/B 50-90% of Healthcare median of 3.11. Mohnish Pabrai would examine if this discount presents opportunity.
-25.62
Negative FCF while Healthcare median P/FCF is -13.53. Seth Klarman would investigate cash flow improvement potential.
-25.62
Negative operating cash flow while Healthcare median P/OCF is -10.31. Seth Klarman would investigate operational improvement potential.
1.76
Fair value ratio 50-90% of Healthcare median of 3.11. Mohnish Pabrai would examine if this gap presents opportunity.
-6.19%
Negative earnings while Healthcare median yield is -1.07%. Seth Klarman would investigate path to profitability.
-3.90%
Negative FCF while Healthcare median yield is -0.71%. Seth Klarman would investigate cash flow improvement potential.